QUICKLINKS AND VIEW OPITONS
Belviq (lorcaserin) side effects: Hypoglycemia in 29% of patients vs 21% with placebo
Saturday, June 22, 2013 2:59 pm Email this article
Hypoglycemia was reported in 29.3% of patients given the weight loss drug, Belviq (lorcaserin), versus 21% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.
Belviq (lorcaserin hydrochloride) Prescribing Information. Revision 08/2012.
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.